TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection — Patricia A. Taylor (2008) | RDL Network
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection
Blood 112(8): 3508-3516
Article 2008 English
Authors
PT
Patricia A. Taylor
ME
Michael Ehrhardt
CL
Christopher J. Lees
Abstract
1 min read
Cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs) are synthetic ODNs with unmethylated DNA sequences that mimic viral and bacterial DNA and protect against infectious agents and tumor challenge. We show that CpG ODNs markedly accelerated graft-versus-host disease (GVHD) lethality by Toll-like receptor 9 (TLR9) ligation of host antigen-presenting cells (APCs), dependent upon host IFNγ but independent of host IL-12, IL-6, or natural killer (NK) cells. Imaging studies showed significantly more green fluorescent protein–positive (GFP+) effector T cells in lymphoid and nonlymphoid organs. In engraftment studies, CpG ODNs promoted allogeneic donor bone marrow (BM) rejection independent of host IFNγ, IL-12, or IL-6. During the course of these studies, we uncovered a previously unknown and critical role of donor BM APCs in modulating the rejection response. CpG ODNs promoted BM rejection by ligation of donor BM, but not host, TLR9. CpG ODNs did not impair engraftment of TLR9−/− BM unless wild-type myeloid (CD11b+) but not B-lineage (CD19+) BM cells were added to the donor inoculum. The importance of donor BM APCs in modulating the strength of the host antidonor rejection response was underscored by the finding that B7-1/B7-2−/− BM was less likely than wild-type BM to be rejected. Collectively, these data offer new insight into the mechanism of alloresponses regulating GVHD and BM rejection.
Laurent Burnier, François Saller, Linda Kadi, Anne C. Brisset, Rocco Sugamele, Lucie Baudino, Françoise Bono, Jean‐Marc Herbert, Peter Carmeliet, M Schapira, Shozo Izui, Anne Angelillo‐Scherrer
Discussion(0)
No comments yet. Be the first to comment.